Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA5A | P35218 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16572564 | 0.82 | CA1 (0.47) | CA1CA2CA5ACA9PTGES2 | |
| SCHEMBL15925025 | 0.81 | CA12 (0.42) | CA1CA2CA9PTGS1PTGS2 | |
| SCHEMBL8770171 | 0.78 | SCN9A (0.45) | CA1CA2CA5APTGES2CA5B | |
| SCHEMBL28511392 | 0.77 | CA12 (0.42) | CA1CA2CA5ACA9PTGS1 | |
| SCHEMBL15668312 | 0.77 | PTGES2 (0.48) | CA1CA2CA9PTGES2PTGS1 | |
| SCHEMBL7211494 | 0.77 | CA2 (0.53) | CA1CA2CA5ACA9PTGS1 | |
| SCHEMBL7211481 | 0.77 | PTGS2 (0.49) | CA1CA2CA5ACA9PTGS1 | |
| SCHEMBL6564249 | 0.75 | ALDH1A1 (0.54) | CA1CA2CA5ACA9PTGS1 | |
| SCHEMBL29700241 | 0.75 | ALDH1A1 (0.54) | CA1CA2CA5ACA9PTGS1 | |
| SCHEMBL7078177 | 0.75 | ALDH1A1 (0.54) | CA1CA2CA5ACA9PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004043917-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | claimed |
| US-9884878-B2 | FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-06 | — | — | US | disclosed |
| US-9745328-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-29 | — | — | US | disclosed |
| US-20150376212-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150259357-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-17 | — | — | US | disclosed |
| US-9079866-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | disclosed |
| US-20140221311-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2542086-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myrexis, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2011109441-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2004043917-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | CA1 993/4885CA2 2402/4885CA5A 288/4885 |
| US-20150376212-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | CA1 3447/4885CA2 4418/4885CA5A 532/4885 |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | CA1 993/4885CA2 2402/4885CA5A 288/4885 |
| US-20150259357-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | CA1 3615/4885CA2 4111/4885CA5A 443/4885 |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | CA1 993/4885CA2 2402/4885CA5A 288/4885 |
| US-20140221311-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | CA1 3615/4885CA2 4111/4885CA5A 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.